Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB	4/14/1968
Gender:	Female
Patient Identifiers:	01234567890ABCD, 012345
Visit Number (FIN):	01234567890ABCD
Collection Date:	00/00/0000 00:00

Antimicrobial Level - Rifabutin by HPLC, Serum or Plasma

ARUP test code 2009363

Antimicrobial Level - Rifabutin Ser/Pla	See Note Performed By: National Jewish Center, Advanced Diag 1400 Jackson St Denver, CO 80206
Rifabutin - Comment	See Note

H=High, L=Low, *=Abnormal, C=Critical

Drug Level	Conc.	Unit	Flags
Rifabutin Level by HPLC	0.42	mcg/mL	

Test Name: Rifabutin Level
Specimen Type: Serum
Time/Date of Last Dose: Not Provided
Dose: Not Provided
Rifabutin Level: 0.42 mcg/mL

Interpretation:
The target range for rifabutin when treating mycobacterial infections is 0.3 to 0.9 mcg/mL at 3 to 4 hours after oral dose. Samples drawn later than 4 hours after the dose may display concentrations below the stated range. Samples drawn earlier than 7 days into treatment with rifabutin may not represent steady-state concentrations.

Rifabutin may be given with food if necessary for patient tolerance. This may reduce the peak concentration, but total absorption does not appear to be significantly changed. If rifabutin must be taken with food, peak blood draws should be delayed until 4 to 5 hours post dose.

Although data are lacking, avoid antacids within 2 hours of rifabutin dosing if possible.

Elevated serum rifabutin concentrations have been reported with concomitant administration of macrolide antibiotics and/or fluconazole and itraconazole. Other medications that inhibit hepatic microsomal enzymes may cause the same interaction.

There is a potential association between uveitis and elevated serum rifabutin concentrations. If the patient reports eye pain, redness or loss of vision, discontinue rifabutin and obtain ophthalmic evaluation. Arthralgias, leukopenia, and skin discoloration also have been associated with elevated rifabutin concentrations.

If the time of the dose and the blood draw were not accurately recorded, accurate interpretation of the concentration is not possible.

For additional information, including methodology, please contact the laboratory.

The performance characteristics for this test have been validated by Advanced Diagnostic Laboratories at National Jewish Health. It has not been cleared or approved by the US Food and Drug Administration.

The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88) as qualified to perform high complexity clinical laboratory testing.
Performed By: National Jewish Center, Advanced Diag
1400 Jackson St
Denver, CO 80206

Rifabutin - Specimen

See Note

Performed By: National Jewish Center, Advanced Diag
1400 Jackson St
Denver, CO 80206

H=High, L=Low, *=Abnormal, C=Critical

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
Antimicrobial Level - Rifabutin Ser/Pla	23-300-402259	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Rifabutin - Comment	23-300-402259	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
Rifabutin - Specimen	23-300-402259	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical